Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 1/20 | 0.34 |
| ▸ | MC5R | P33032 | 1/20 | 0.34 |
| ▸ | MC3R | P41968 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 2/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17354190 | 0.93 | DRD2 (0.32) | MC4RMC5RMC3RDRD4DRD2 | |
| SCHEMBL13875 | 0.92 | PLK4 (0.34) | MC4RMC5RMC3R | |
| SCHEMBL17354352 | 0.86 | PLK4 (0.33) | MC4RMC5RMC3RDRD4DRD2 | |
| SCHEMBL14122 | 0.85 | PLK4 (0.32) | — | |
| SCHEMBL13622 | 0.82 | MC4R (0.35) | MC4RMC5RMC3R | |
| SCHEMBL17354250 | 0.79 | KDM1A (0.31) | — | |
| SCHEMBL13899 | 0.79 | PLK4 (0.34) | — | |
| SCHEMBL13793 | 0.78 | MC4R (0.39) | MC4RMC5RMC3R | |
| SCHEMBL14850256 | 0.76 | MAP4K4 (0.41) | — | |
| SCHEMBL13700 | 0.76 | MC4R (0.35) | MC4RMC5RMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9845297-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-9845297-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2016-02-04 | — | — | US | disclosed |
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2016-02-04 | — | — | US | disclosed |
| US-9216979-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216979-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20130090326-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090326-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2011047323-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090326-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MPO, LPO, CAT | MC4R 2989/4885MC5R 3036/4885MC3R 3163/4885 |
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MPO, LPO, CAT | MC4R 2989/4885MC5R 3036/4885MC3R 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.